Mantle Cell Lymphoma

Findings suggest that liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features, who have limited treatment options.

Matthew Matasar, MD, discussed the rationale and findings of the doublet consisting of ibrutinib and venetoclax for the treatment of mantle cell lymphoma.

High complete response rates and low incidences of cytokine release syndrome and neurological events were observed when patients with relapsed or refractory mantle cell lymphoma were treated with lisocabtagene maraleucel.

In an interview with Targeted Oncology, Andre Goy, MD, discussed the potential of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory mantle cell lymphoma and how 2 studies provide support for use of the agent in this patient population.

Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival and complete response rate.

Treatment with zanubrutinib, obinutuzumab, and venetoclax, also known as BOVen, showed promising safety and efficacy in treatment-naive patients with TP53-mutant mantle cell lymphoma.

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.

Maintenance therapy with lenalidomide and rituximab is safe and feasible for the treatment of patients with mantle cell lymphoma.

Findings from a phase 2 study show that sequential minimal residual disease assessment is a powerful prognostic tool in patients with mantle cell lymphoma.

The CAR-HEMATOTOX score was positively associated with identifying the risk of poor treatment outcomes for patients with mantle cell lymphoma treated with chimeric antigen receptor T-cell therapy.

In an interview with Targeted Oncology, Nirav Shah, MD, discussed long-term follow-up results from the phase 1/2 BRUIN study and how the approval of pirtobrutinib has changed the MCL treatment landscape.

Lisocabtagene maraleucel showed activity in patients with relapsed/refractory mantle cell lymphoma, according to findings from the TRANSCEND-NHL-001 study.

In an interview with Targeted Oncology, Hun Ju Lee, MD, discussed the encouraging responses shown with the combination of zilovertamab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia, and highlighted other studies making headway in the field.

In an interview with Targeted Oncology, Tycel Phillips, MD, discussed the initial results of the addition of acalabrutinib to bendamustine and rituximab to treat patients with mantle cell lymphoma.

Michael Wang, MD, discusses the background of the phase 3 BRUIN MCL-321 trial and how positive results may shape the future of the mantle cell lymphoma space.

The addition of acalabrutinib to bendamustine and rituximab met tolerability and safety end points in a phase 1b trial, as well as promising efficacy results in patients with either treatment-naive or relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses what led to the start of the phase 3 BRUIN MCL-321 trial for patients with mantle cell lymphoma.

Hun Ju Lee, MD, discusses the early results of the dose finding and safety study of zilovertamab plus ibrutinib for patients with mantle cell lymphoma as well as chronic lymphocytic leukemia and marginal zone lymphoma.

In an interview with Targeted Oncology, Mitchell Smith, MD, PhD, discussed what the findings from the ECOG-ACRIN E1411 trial in patients with mantle cell lymphoma means for the future of the space, and where research is heading.

The TRANSCEND FL and TRANSCEND NHL 001 studies of lisocabtagene maraleucel met its primary end point of overall response rate and secondary end point of complete response rate in patients with follicular lymphoma and B-cell non-Hodgkin lymphoma.

Martin Dreyling, MD, discusses the next steps for research with ibrutinib in the mantle cell lymphoma space following the presentation of data from the phase 3 TRIANGLE study.

Mixed study results for ibrutinib have led the developer to voluntarily withdraw the agent from the United States market for the treatment of mantle cell and marginal zone lymphoma subgroups.

Mitchell Smith, MD, PhD, discusses how the updated results of the phase 2 ECOG-ACRIN E1411 trial of patients with previously untreated mantle cell lymphoma can be interpreted in context of data supporting the use of the Bruton’s tyrosine kinase inhibitor ibrutinib in this setting.

Clinical trials exploring regimens without ASCT consolidation in young patients with MCL are needed, and maintenance with rituximab should be considered for patients after first-line treatment with bendamustine plus rituximab and R-CHOP

Lori Leslie, MD, describes the cohorts of the phase 2 ZUMA-2 study and discusses the potential impact of brexucabtagene autoleucel in the mantle cell lymphoma landscape.

Mitchell Smith, MD, PhD, discusses the updated results of the phase 2 ECOG-ACRIN E1411 trial of patients with previously untreated mantle cell lymphoma.

A 90-day complete response rate of 92% was observed with bispecific CAR T-cell therapy for patients with relapsed/refractory mantle cell lymphoma.